巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Zosano Pharma Corp

    ZSAN
    1.970
    0.140
    6.64%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Zosano Pharma Corp - 延遲價格・最後更新於 24/05 8:25
    最高位
    2.020
    最低位
    1.970
    開市價
    --
    前收市價
    2.110
    成交量(千)
    1.75
    成交額(百萬)
    0.03
    買入
    --
    賣出
    5.000
    每手股數
    --
    市值(百萬)
    9.66
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    37.450 - 1.330
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Zosano Pharma Corp
    證券代碼
    ZSAN.US
    所屬板塊
    Biotechnology
    公司業務
    Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.
    發行量
    171455813
    公司總部
    34790 Ardentech Court
    公司網址
    https://www.zosanopharma.com
    公司電郵
    bd@zosanopharma.com
    公司電話
    +1 510 745-1200
    暫無內容

    關於

    Zosano Pharma Corp(ZSAN.US)所屬的行業板塊為Biotechnology。
    Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.
    詳細公司背景可參考: https://www.zosanopharma.com